Dasatinib Intermediate CAS 302964-08-5 Purity >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of N-(2-Chloro-6-Methylphenyl)-2-[(6-Chloro-2-Methyl-4-Pyrimidinyl)amino]-5-Thiazolecarboxamide (CAS: 302964-08-5) with high quality, intermediate of Dasatinib (CAS: 302962-49-8) and Dasatinib Monohydrate (CAS: 863127-77-9). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Dasatinib intermediates, Please contact: alvin@ruifuchem.com
Chemical Name | N-(2-Chloro-6-Methylphenyl)-2-[(6-Chloro-2-Methyl-4-Pyrimidinyl)amino]-5-Thiazolecarboxamide |
Synonyms | Dasatinib Int N-1; Dasatinib Dichloro; 2-[(6-Chloro-2-Methylpyrimidin-4-yl)amino]-N-(2-Chloro-6-Methylphenyl)thiazole-5-Carboxamide |
Stock Status | In Stock, Production Capacity 15 Tons per Year |
CAS Number | 302964-08-5 |
Molecular Formula | C16H13Cl2N5OS |
Molecular Weight | 394.27 g/mol |
Melting Point | 333.0~335.0℃ |
Density | 1.516±0.06 g/cm3 |
Store Under Inert Gas | Store Under Inert Gas |
Sensitive | Air Sensitive, Heat Sensitive |
COA & MSDS | Available |
Origin of Product | Shanghai, China |
Product Categories |
Pharmaceutical Intermediates |
Brand | Ruifu Chemical |
Items | Specifications | Results |
Appearance | Off-White to Light Yellow Solid | Complies |
Purity / Analysis Method | >98.0% (HPLC) | 99.10% |
Infrared Spectrum | Consistent with Structure | Complies |
NMR Spectrum | Consistent with Structure | Complies |
Conclusion | The product has been tested and complies with the given specifications | |
Application: Intermediate of Dasatinib (CAS: 302962-49-8) and Dasatinib Monohydrate (CAS: 863127-77-9) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed. Store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
N-(2-Chloro-6-Methylphenyl)-2-[(6-Chloro-2-Methyl-4-Pyrimidinyl)amino]-5-Thiazolecarboxamide (CAS: 302964-08-5), intermediate of Dasatinib (CAS: 302962-49-8) and Dasatinib Monohydrate (CAS: 863127-77-9). Dasatinib is used in all the stages of chronic myelogenous leukemia that have been treated, including Imatinib Mesylate / Gleevec resistant or intolerable (chronic phase, accelerated phase, lymphoid cell blast phase and myeloid leukemia). Cell blast stage) adult patients. At the same time, the FDA has also approved Dasatinib to treat Philadelphia chromosome-positive adult patients with acute lymphoblastic leukemia who are resistant or intolerant to other therapies through normal procedures.